Skip to main content Accessibility help
×
Home

The Aftercare of the Patient with the Neuroleptic Malignant Syndrome

  • Dov Aizenberg (a1), Arieh Shalev (a2) and Hanan Munitz (a2)

Summary

The neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction to neuroleptic drugs, made up of hyperthermia, muscular rigidity, disturbance of level of consciousness and autonomic dysfunction. It is potentially lethal and should be kept in mind whilst using anti-psychotic drugs; as most patients treated by them require further anti-psychotic treatment, the clinician faces the problem of treating those patients after a NMS episode, yet reports in the literature have generally neglected the problem of late management. A patient suffering from a psychosis and NMS is presented, and a rationale for management offered.

Copyright

References

Hide All
Allan, R. N. & White, H. C. (1972) Side effects of parenteral long-acting phenothiazines. British Medical Journal, 1, 221.
Bernstein, R. A. (1979) Malignant neuroleptic syndrome: an atypical case. Psychosomatics, 20, 840846.
Caroff, S. N. (1980) The neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 41, 7983.
Caroff, S., Rosenberg, H. & Gerber, J. C. (1983) Neuroleptic malignant syndrome and malignant hyperthermia. Lancet, 333, 224.
Coons, D. J., Hillman, F. J. & Marshall, R. W. (1982) Treatment of neuroleptic malignant syndrome with dantrolene sodium: a case report. American Journal of Psychiatry, 139, 944945.
Cope, R. V. & Gregg, E. M. (1983) The neuroleptic malignant syndrome. British Medical Journal, 286, 1938.
Dillon, J. B. (1972) Parenteral long-acting phenothiazines. British Medical Journal, i, 807.
Goekoop, J. G. & Carbaat, P. A.Th. (1982) Treatment of neuroleptic malignant syndrome with dantrolene. Lancet, 332, 4950.
Henderson, V. W. & Wooten, G. F. (1981) Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology (NY), 31, 132137.
Itoh, H., Oktsuk, A.N., Ogita, K., Yagi, G., Miura, S. & Koga, (1977) Malignant neuroleptic syndrome—its present status in Japan and clinical problems. Folia Psychiatrica et Neurologica Japonica, 31, 565567.
Jesse, S. S., Anderson, G. F. (1983) ETC in the neuroleptic malignant syndrome: case report. Journal of Clinical Psychiatry, 44, 186188.
Meltzer, H. Y. (1973) Rigidity, hyperpyrexia and coma following fluphenazine enanthate. Psychopharmacologia (Berlin). 29, 337346.
Powers, P., Douglas, T. S. & Waziri, R. (1976) Hyperpyrexia in catatonic states. The Journal of Nenous and Mental Disease, 37, 359361.
Regestein, Q. R., Alpert, J. S. & Reich, P. (1979) Sudden catatonic stupor with disastrous outcome. Journal of American Medical Association, 238, 618620.
Smego, R. A. & Durack, D. T. (1982) The neuroleptic malignant syndrome. Archives of Internal Medicine, 142, 11831185.
Szabadi, E. (1984) Neuroleptic malignant syndrome. British Medical Journal, 288, 13991400.

The Aftercare of the Patient with the Neuroleptic Malignant Syndrome

  • Dov Aizenberg (a1), Arieh Shalev (a2) and Hanan Munitz (a2)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

The Aftercare of the Patient with the Neuroleptic Malignant Syndrome

  • Dov Aizenberg (a1), Arieh Shalev (a2) and Hanan Munitz (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *